Scienture Corp (SCNX): Rasio rega marang prakiraan pendapatan

Lambang korporat lan logo Scienture Corp (SCNX)

Scienture Holdings Inc develops enhanced drug formulations in the US, leveraging patent protection. Experienced management is preparing the company for clinical trials. The business ensures high customer loyalty through deep software customization to meet regulatory standards. The company's expected P/S, illustrated in this chart on GURU.Markets, helps assess the asset's value, where 7.40 captures the current value of the indicator.

Scienture Holdings - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep SCNX (periode 24.09.2024 - 15.11.2026)

Rincian metrik komprehensif lan analitis scienture.com (SCNX)

Analisis wiwitan perusahaan:SCNX (Scienture Holdings Inc.)
Sampel barang Scienture Holdings Inc

To protect capital from volatility between earnings reports, it is crucial for investors to understand the premium the market is pricing into future sales. The optimization of therapeutic drug profiles at Scienture Holdings Inc (SCNX) reduces development risks, rendering the forward P/S ratio an accurate tool for valuing each dollar of expected revenue, which helps avoid overpaying for management and prevents asset freezes.

Karo sapa Scienture Holdings Inc saingan

Rasio rega marang prakiraan pendapatan Veeva Corp VEEV|Rasio rega marang pendapatan sing dikarepake DOCS (Doximity, Inc.)|HQY: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan WAY (waystar.com)|CorVel Corp. (CRVL) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Privia Health (PRVA)|Rasio rega marang prakiraan pendapatan Huron Corp|Kapitalisasi marang prakiraan pendapatan CERT (Certara Corp)|Rasio rega marang prakiraan pendapatan Omnicell (OMCL)|GoodRx Holdings, Inc. - Kapitalisasi marang prakiraan pendapatan|Schrödinger - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Phreesia Inc (PHR)|OMDA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan EVH (Evolent Health, Inc.)|HSTM: Multiplikator Forward P/S|DH: Rasio rega marang pendapatan sing dikarepake|CCSI (Consensus) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan AGL|Multiplikator Forward P/S ABSI|Rasio kapitalisasi marang dodolan sing dikarepake So-Young Corp|Rasio rega marang prakiraan pendapatan National Research NRC|SPOK - Multiplikator forward rega marang pendapatan|optimizerx.com - Multiplikator Forward P/S|Prakiraan rega marang pendapatan TruBridge (TBRG)|SLP: Multiplikator Forward P/S|SOPH - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan HCAT|CCLD (CareCloud) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan researchsolutions.com (RSSS)|DLHC (DLH Holdings) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan OneMedNet ONMD|Rasio rega marang pendapatan sing dikarepake HCTI (Healthcare Triangle Corp)|iSpecimen Corp - Multiplikator Forward P/S|Rega forward marang dodolan BFRG (bullfrogai.com)|WORX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan MSP Recovery|Rasio rega marang prakiraan pendapatan icoreconnect.com|MEDS: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Orgenesis Inc. (ORGS)|Rasio kapitalisasi marang dodolan sing dikarepake R1 RCM, Inc.|Multiplikator Forward P/S SHCR (sharecare.com)|Rasio kapitalisasi marang dodolan sing dikarepake Streamline Health Solutions, Inc. (STRM)|SYRA - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Apollo Medical Holdings Inc. AMEH|Model N (MODN) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan NXGN